<DOC>
	<DOCNO>NCT02923700</DOCNO>
	<brief_summary>Platelet-rich Plasma ( PRP ) exploit biologic agent currently use treatment osteoarthritis ( OA ) different joint , particular knee OA . In previous study , show potential reduce pain improve functional status patient treat simple intra-articular injection . However , several PRP formulation currently available clinical use , therefore difficult compare data come trial use different product . The debated aspect concern PRP formulation role leukocyte , might stimulate early inflammatory response joint due release metalloproteases pro-inflammatory cytokine . The investigator hypothesize presence leukocyte PRP could clinically relevant term outcome , present double blind randomize control trial design compare leukocyte-rich leukocyte-poor PRP injection treatment knee OA . A power analysis perform primary endpoint IKDC ( International Knee Documentation Committee ) subjective score improvement 12-month follow-up PRP . From pilot study , standard deviation 15.2 point find . With alpha error 0.05 , beta error 0.2 minimal clinically significant difference 6.7 point correspond 1/3 documented mean improvement , minimum sample size 83 group . Considering possible drop 15 % , 96 patient per group require total 192 patient , select accord well-defined inclusion criterion ( see 'Eligibility criterion ' section ) . Patients assign two different treatment group , accord randomization list . The first group treatment consist three weekly intra-articular injection autologous leukocyte-rich PRP , whereas second group patient treat three intra-articular injection leukocyte-poor PRP . PRP obtain follow procedure : 300-ml autologous venous blood sample undergo 2 centrifugation ( first 1480 rpm 6 minute separate erythrocyte , second 3400 rpm 15 minute concentrate platelet ) produce 20 ml leukocyte-rich PRP . In case patient allocate receive leukocyte-poor PRP , special filter use separate leukocyte obtain leukocyte-poor PRP . The total amount PRP divide 4 small unit 5 ml . One unit send laboratory analysis platelet concentration quality test , 3 unit store -30° C. One week PRP production , injective treatment start , 3 weekly injection . At moment injection syringe properly cover prevent patient discover substance receiving . After injection , patient send home instruction limit use leg least 24 h use cold therapy/ice affect area relieve pain . During period , use non-steroidal medication forbidden . Patients prospectively evaluate basally 2 , 6 , 12 month follow-up use clinical subjective score objective parameter determine clinical outcome ( see 'Outcome measure ' section ) . Patient satisfaction adverse event also report . All clinical evaluation perform medical staff involve injective procedure , order keep study double blind . At end study , nature inject substance reveal patient .</brief_summary>
	<brief_title>Leukocyte-rich PRP v Leukocyte-poor PRP Treatment Knee Cartilage Degeneration : Randomized Controlled Trial</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>1. patient affected monolateral symptomatic knee articular degenerative pathology history chronic ( least 4 month ) pain swell ; 2. imaging finding degenerative change joint ( osteoarthritis chondropathy Kellgren Lawrence Score 0 3 Xray evaluation ) . age &gt; 80 year ; KellgrenLawrence score Xray evaluation &gt; 3 ; major axial deviation ( varus &gt; 5° , valgus &gt; 5° ) , systemic disorder diabetes , rheumatoid arthritis , haematological disease ( coagulopathy ) , severe cardiovascular disease , infection , immunodepression ; patient therapy anticoagulant antiaggregants ; use NSAIDs 5 day blood donation ; patient Hb value &lt; 11 g/dl platelet value &lt; 150,000/mmc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>platelet rich plasma</keyword>
	<keyword>intra-articular injection</keyword>
	<keyword>leukocyte</keyword>
</DOC>